BioCardia (BCDA)
(Delayed Data from NSDQ)
$2.49 USD
-0.21 (-7.78%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.49 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.49 USD
-0.21 (-7.78%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.49 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Zacks News
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 4.76% and 72.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will BioCardia, Inc. (BCDA) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCardia, Inc. (BCDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 14.29% and 31.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 48.39% and -58.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.